Atrinsic (NASDAQ:PTIX – Get Free Report) and Spero Therapeutics (NASDAQ:SPRO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.
Analyst Ratings
This is a breakdown of current recommendations for Atrinsic and Spero Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atrinsic | 1 | 0 | 0 | 0 | 1.00 |
| Spero Therapeutics | 1 | 1 | 0 | 0 | 1.50 |
Profitability
This table compares Atrinsic and Spero Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atrinsic | N/A | N/A | -379.72% |
| Spero Therapeutics | -108.11% | -125.91% | -57.58% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atrinsic | N/A | N/A | -$5.53 million | ($7.95) | -0.06 |
| Spero Therapeutics | $47.98 million | 2.55 | -$68.57 million | ($0.79) | -2.75 |
Atrinsic has higher earnings, but lower revenue than Spero Therapeutics. Spero Therapeutics is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
8.0% of Atrinsic shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 8.0% of Atrinsic shares are held by company insiders. Comparatively, 5.5% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Atrinsic has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
Summary
Spero Therapeutics beats Atrinsic on 6 of the 11 factors compared between the two stocks.
About Atrinsic
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
About Spero Therapeutics
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Atrinsic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrinsic and related companies with MarketBeat.com's FREE daily email newsletter.
